【编者按】2019年随着科创板的推进落地，更多成规模的IVD高新技术企业有望比预期提前上市，4月4日，POCT企业热景生物递交的科创板招股书获得受理，标志着体外诊断行业资产证券化再提速，将对国内市场竞争格局产生深远影响，加速创新型中小企业和龙头企业对外扩张、转型升级与行业整合的进程。本文来源于火石创造，作者韩佳；经亿欧大健康编辑，供行业人士参考。体外诊断（IVD）是全球医疗器械最大的子领域，国内有很多“小鱼小虾”般的中小企业活跃，但从全球IVD产业演进历史看，未来十年国内IVD行业很可能由“百舸争流”逐步演变为“水大鱼大，少有小虾”的产业生态。未来，我们或将看到更多“掌握核心科技”的创新企业活...
[Editor's Note] In 2019, with the development of science and technology innovation board, more large-scale IVD high-tech enterprises are expected to be listed earlier than expected. On April 4, POCT hot biotechnology submitted the science and technology innovation board prospectus accepted, which indicates that the asset securitization of in vitro diagnosis industry is accelerating again, which will have a far-reaching impact on the domestic market competition pattern, and accelerate innovative SMEs and leading enterprises to pair. External expansion, transformation and upgrading and industry integration process. This article originates from the creation of flint, by Han Jia, and is edited by Euro 100 million Health University for reference by professionals. In vitro diagnosis (IVD) is the largest sub-field of medical devices in the world. There are many small and medium-sized enterprises like "small fish and shrimp" active in China. However, judging from the evolution history of global IVD industry, it is likely that the domestic IVD industry will gradually evolve from "100% competition" to "big fish with little shrimp" in the next decade. In the future, we may see more innovative business activities of "mastering core technology".
